Breast cancer in Morocco: A literature review

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 3, 2014, Pages 1067-1074

  Slaoui, Meriem ^a,b   Razine, Rachid ^a   Ibrahimi, Azeddine ^a   Attaleb, Mohammed ^b   El Mzibri, Mohammed ^b   Amrani, Mariam ^a  

^a MOHAMMED V UNIVERSITY   (Morocco)

^b CENTRE NATIONAL DE L ENERGIE DES SCIENCES TECHNIQUES NUCLEAIRES   (Morocco)

Author keywords

Breast cancer; Epidemiology; Genetic; Molecular treatment; Morocco

Indexed keywords

BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; CD44 PROTEIN, HUMAN; HERMES ANTIGEN; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUC1 PROTEIN, HUMAN; MUCIN 1; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOC PROTEIN, HUMAN; TUMOR MARKER;

BREAST TUMOR; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATORY BREAST CANCER; MALE; MOROCCO; MORTALITY; SHORT SURVEY; TRIPLE NEGATIVE BREAST CANCER;

ANTIGENS, CD44; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS, MALE; DISEASE-FREE SURVIVAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MOROCCO; MUCIN-1; RHO GTP-BINDING PROTEINS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896811862     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.3.1067     Document Type: Short Survey

References (71)

1. Abahssain H, Kairouani M, Gherman R, et al (2010). Granulosa cell tumor of the ovary and antecedent of adjuvant tamoxifen use for breast cancer. World J Surg Oncol, 8, 67-70.
2. Abahssain H, Lalya I, El M'Rabet FZ, et al (2010). Breast cancer in moroccan young women: a retrospective study. BMC Research Note. 3, 286-94.
3. Abbass F, Akasbi Y, Znati K, et al (2012). Classification moleculaire du cancer du sein au Maroc. Pan Afr Med J. 13, 91-105.
4. Abbass F, Bennis S, Znati K, et al (2011). Epidemiological and biologic profile of breast cancer in Fez-Boulemane, Morocco. East Mediterr Health J, 17, 12.
5. Agarwal G, Pradeep PV, Aggarwal V, et al (2007). Spectrum of breast cancer in Asian women. World J Surg, 31, 1031-40.
6. Ahbeddou N, Belbaraka R, Fetohi M, Errihani H (2011). Tamoxifen-induced hepatotoxicity. Indian J Cancer, 48, 385.
7. Aitelhaj M, Lkhouyaali S, Rais G (2013). Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients. BMC Research Notes, 6,339-44.
8. Akasbi Y, Bennis S, Abbass F, et al (2011). Clinicopathological, therapeutic and prognostic features of the triple-negative tumors in moroccan breast cancer patients (experience of Hassan II university hospital in Fez). BMC Res Notes, 4, 500.
9. Atoum M, Nimer N, Abdeldayem S, Nasr H (2012). Relationships among serum CA15-3 tumor marker, TNM staging, and estrogen and progesterone receptor expression in benign and malignant breast lesions. Asian Pac J Cancer Prev, 13, 857-60.
10. Bellakhdar J (1997). La pharmacopee marocaine traditionnelle. Medecine arabe ancienne et savoir populaire. Ibis Press.
11. Bennis S, Abbass F, Akasbi Y, et al (2012) Prevalence of molecular subtypes and prognosis of invasive breast cancer in north-east of Morocco: retrospective study. BMC Res Notes, 5, 436.
12. Bensouda Y, Andre F, Boulet T, et al (2009). Prevalence de l'elevation du CA 15-3 lors de la rechute metastatique des cancers du sein: correlation avec l' expression des recepteurs hormonaux et de Her2. Bull Cancer, 96, 923-8.
13. Bensouda Y, Ismaili N, Ahbeddou N, et al (2011). Chimiotherapie neoadjuvante par anthracyclines dans le cancer du sein:facteurs predictifs de reponse. Gynecol Obstet Fertil, 39, 81-6.
14. Blamey RW, Hornmark-Stenstam B, et al (2010). ONCOPOOLA European database for 16,944 cases of breast cancer. Eur J Cancer, 46, 56-71.
15. Boufettal H, Noun M, Samouh N (2010). Cancer du sein chez la femme jeune au Maroc. Cancer Radiother, 14, 698-703.
16. Boulaamane L, Boutayeb S, Errihani H (2012). Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study. BMC Res Notes, 5, 162.
17. Bourhafour M, Belbaraka R, Souadka A, et al (2011). Male breast cancer: a report of 127 cases at a Moroccan institution. BMC Res Notes, 4, 219
18. Boussen H, Bouzaiene H, Hassouna JB, et al (2010). Inflammatory Breast Cancer in Tunisia. Cancer, 116, 2730-5.
19. Chalabi N, Bernard-Gallon DJ, Bignon YJ, et al (2008). Comparative clinical and transcriptomal profiles of breast cancer between French and South Mediterranean patients show minor but significative biological differences. Cancer Genomics Proteomics, 5, 253-61.
20. Chaouki W, Leger DY, Eljastimi J, et al (2010). Antiproliferative effect of extracts from Aristolochia baetica and Origanum compactum on human breast cancer cell line MCF-7. Pharm Biol, 48, 269-74.
21. Chaouki W, Leger DY, Liagre B, et al (2009). Roots of Daphne gnidium L. inhibit cell proliferation and induce apoptosis in the human breast cancer cell line MCF-7. Pharmazie, 64, 542-6.
22. Cherbal F, Bakoura R, Adaneb S, et al (2010). BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families, Dis Markers, 28, 377-84.
23. Cutuli B, Cohen-Solal Le-Nir C, Serin D, et al (2010). Male breast cancer: Evolution of treatment and prognostic factors. Analysis of 489 cases. Crit Rev Oncol Hematol, 73, 246-54.
24. Diakite B, Tazzite A, Hamzi K, et al (2012). Methylenetetrahydrofolate Reductase C677T polymorphism and breast cancer risk in Moroccan women. African Health Sciences, 12, 204-9.
25. El Omari-Alaoui H, Lahdiri I, Nejjar I, et al (2002). Male breast cancer: A report of 71 cases. Cancer Radiother, 6, 349-51.
26. El Youbi BAM, Bourhafour M, Errihani H (2013). Le cancer du sein chez l'homme au Maroc: quels impacts psychosociaux?. Pan African Med J, 14, 150-2.
27. Elghissassi I, Inrhaoun H, Vignot S, et al (2009). Reduction in HER-2 protein expression in a breast tumor HER-2 positive after only one injection of Trastuzumab: a case report. Cases J, 2, 8099.
28. Ergul E, Sazci A, Utkan Z, Canturk NZ (2003). Polymorphisms in the MTHFR gene are associated with breast cancer. Tumour Biol, 24, 286-90.
29. Errihani H, Boutayeb S, Farik M, et al (2008). The inflammatory breast cancer-Moroccan experience. Eur J Cancer Supplements, 6, 76.
30. Forges T, Monnier-Barbarino P, Alberto JM, et al (2007). Impact of folate and homocysteine metabolism on human reproductive health. Hum Reprod Update, 13, 225-38.
31. Fornander T, Rutqvist LE, Cedermark B, et al (1989). Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet, 1, 117-9.
32. Foulkes WD, Smith IE, Reis-Filho JS (2010). Triple-Negative Breast Cancer New England Journal of Medicine. N Engl J Med, 363, 1938-48.
33. González-Tejero MR, Casares-Porcel M, Sánchez-Rojas CP, et al (2007). Medicinal plants in the Mediterranean area: synthesis of the results of the project Rubia. J Ethnopharmacol, 116, 341-57.
34. Hakem A, Sanchez-Sweatman O, You-Ten A, et al (2005). RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev, 19, 1974-9.
35. IARC Globocan, International Agency for Research on Cancer, 2008.
36. Ismaili N, Elmajjaoui S, Lalya I, et al (2010). Anthracycline and concurrent radiotherapy as adjuvant treatment of operable breast cancer: a retrospective cohort study in a single institution. BMC Res Notes, 3, 247.
37. John EM, Miron A, Gong G, et al (2007). Prevalence of pathogenic BRCA1 mutation carriers in 5 U.S. racial/ethnic groups. JAMA, 298, 2869-76.
38. Kao J, Conzen SD, Jaskowiak NT, et al (2005). Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials. Int J Radiat Oncol Biol Phys, 61, 1045-53.
39. Kleer CG, Zhang Y, Pan Q, et al (2004). WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res, 6, 110-5.
40. Laamiri FZ, Otmani A, Ahid S, Barakat A (2013). Lipid profile among Moroccan overweight women and breast cancer: a case-control study. Int J Gen Med, 6, 439-45.
41. Laarabi FZ, Jaouad IC, Ouldim K, et al (2011). Genetic testing and first presymptomatic diagnosis in Moroccan families at high risk for breast/ovarian cancer. Oncol Lett, 2, 389-93.
42. Laraqui A, Uhrhammer N, Lahlou-Amine I, et al (2013). Mutation Screening of the BRCA1 Gene in Early Onset and Familial Breast/Ovarian Cancer in Moroccan Population. Int J Med Sci, 10, 60-7
43. Le Registre des Cancers de Rabat 2006-2008. Edition Juin 2012. Le registre des Cancers de la Region du grand Casablanca 2005-2006-2007. Edition 2012.
44. Louderbough JM, Schroeder JA (2011). Understanding the dual nature of CD44 in breast cancer progression. Molecular Cancer Research, 9, 1573-86.
45. Mahfoudh W, Bouaouina N, Ben Ahmed S, et al (2011). Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population. Mol Biol Rep, 39, 1037-46.
46. Maruti SS, Ulrich CM, Jupe ER, White E (2009). MTHFR C677T and postmenopausal breast cancer risk by intakes of one-carbon metabolism nutrients: a nested case-control study. Breast Cancer Res, 11, 91.
47. Merrill RM, Capocaccia R, Feuer EJ, Mariotto A (2000). Cancer prevalence estimates based on tumour registry data in the Surveillance, Epidemiology, and End Results (SEER) program. Int J Epidemiol, 29, 197-207.
48. Miki Y, Swensen J, Shattuck-Eidens D, et al (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266, 66-71.
49. Morgan DA, Refalo NA, Cheung KL (2011). Strength of ERpositivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy. The Breast, 20, 215-9.
50. Mrabti H, El Ghissassi I, El Hassani K, et al (2010). Chimiotherapie neo-adjuvante par doxorubicine et vinorelbine dans le traitement d'un cancer du sein pendant la grossesse: cas clinique et revue de la litterature. Oncologie, 12, 26-9.
51. Muller D, Bonaiti-Pellie C, Abecassis J, Stoppa-Lyonnet D, Fricker JP (2004). BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect. Fam Cancer, 3, 15-20.
52. Nokes BT, Cunliffe HE, Lafleur B, et al (2013). In Vitro Assessment of the Inflammatory Breast Cancer Cell Line SUM 149: Discovery of 2 Single Nucleotide Polymorphisms in the RNase L Gene. J Cancer, 4, 104-6.
53. O'Shaughnessy J, Miles D, Gray RJ, et al (2010). A metaanalysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol, 28 (suppl).
54. Palomba G, Pisano M, Cossu A, et al (2005). Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian breast cancer patients through a hospital-based screening. Cancer, 104, 1172-9.
55. Qi X, Ma X, Yang X, et al (2010). Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk: a metaanalysis from 41 studies with 16,480 cases and 22,388 controls. Breast Cancer Res Treat, 123, 499-506.
56. Rais G, Raissouni S, Aitelhaj M, et al (2012). Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology. BMC Women's Health, 12, 35.
57. Ramunas Janavičius (2010). Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J, 1, 397-412.
58. Risch HA, McLaughlin JR, Cole DE, et al (2006). Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst, 98, 1694-706.
59. Roa BB, Boyd AA, Volcik K, Richards CS (1996). Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet, 14, 185-7.
60. Soliman AS, Kleer CG, Mrad K, et al (2012). Inflammatory breast cancer in North Africa: Comparison of clinical and molecular epidemiologic characteristics of patients from Egypt, Tunisia, and Morocco. Breast Dis, 33, 159-69.
61. Sutherland S, Ashley S, Walsh R, et al (2010). Inflammatory breast cancer the Royal Marsden hospital experience. Cancer. 116, 2815-20.
62. Tazi MA, Er-Raki A, Benjaafar N (2013). Cancer incidence in Rabat, Morocco: 2006-2008. Cancer, 7, 338-51.
63. Tazzite A, Jouhadi H, Nadifi S, et al (2012). BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: Novel mutations and unclassified variants. Gynecol Oncol, 125, 687-92.
64. Tazzite A, Jouhadi H, Saiss K, et al (2013). Relationship between family history of Breast Cancer and clinicopathological features in Moroccan patients. Ethiop J Health Sci, 23, 2.
65. Troudi W, Uhrhammer N, Sibille C, et al (2007). Contribution of the BRCA1 and BRCA2 mutations to breast cancer in Tunisia. J Hum Genet, 52, 915-20.
66. Uhrhammer N, Abdelouahab A, Lafarge L, et al (2008). BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases. Int J Med Sci, 5, 197-202.
67. Wooster R, Bignell G, Lancaster J (1995). Identification of the breast cancer gene BRCA2. Nature, 378, 789-91.
68. Yahyaoui O, Guerbaoui M, Oudghiri M (2001). Relation entre envahissement ganglionnaire dans les cancers du sein et du col uterin et le taux d'expression du CD44-H evaluee par methode immunohistochimique. Gynecol Obstet Fertil, 29, 422-7.
69. Yoshida K, Miki Y (2004). Role of BRCA1 and BRCA2 as regulators of DNA repair, tran-scription, and cell cycle in response to DNA damage. Cancer Sci, 95, 866-71.
70. Zhang J, Qiu LX, Wang ZH, et al (2010). MTHFR C677T polymorphism associated with breast cancer susceptibility: a meta-analysis involving 15,260 cases and 20,411 controls. Breast Cancer Res Treat, 123, 549-55.
71. Znati K, Bennis S, Abass F, et al (2012). Cancer du sein chez la femme jeune dans le Nord-Est du Maroc. Gynecol Obstet Fertil [Epub ahead of print].